Michael Barbella, Managing Editor09.07.22
The U.S. Patent & Trademark Office has issued three new patents to ENDRA Life Sciences Inc. for its Enhanced UltraSound (TAEUS).
Patent Nos. 11379343 (the ‘343 patent), 11392479 (the ‘479 patent) and 11405470 (the ‘470 patent) are titled, “Methods and Systems for Exchange of Equipment Performance Data.”
“We are pleased to be issued these three patents that, along with a previously issued U.S. patent, provide broad protection for our proprietary method to transfer equipment performance data to cloud-based services. In addition to protecting data management for our TAEUS system, these patents provide licensing opportunities with other equipment manufacturers,” ENDRA Chairman and CEO Francois Michelon said. "We continue to enhance our intellectual property portfolio to protect our technology in priority global markets. Our portfolio currently includes 53 patents issued globally, of which 31 patents are issued in the U.S.”
These three newly issued patents are part of a patent family that protects ENDRA’s proprietary method and system for acquiring, analyzing, and sharing data in the cloud. The ‘343 and ‘479 patents protect ENDRA's data sharing capabilities that are specific to the medical imaging industry. The ‘470 patent builds upon the company’s U.S. Patent No. 11314617 (the ‘617 patent). Both the ‘470 and ‘617 patents have claims that are narrower than the ‘343 and ‘479 patents and apply to industries outside of medical imaging. The ‘470 patent broadens ENDRA’s coverage from devices “not having internet connectivity” (as described in the ‘617 patent) to devices that are “communicatively insulated.”
ENDRA Life Sciences is the pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS), a technology being developed to visualize tissue like MRI, but a fraction of the cost and at the point of patient care. TAEUS is designed to work in concert with more than 500,000 ultrasound systems currently in use globally. TAEUS is initially focused on measuring liver fat as a means to assess and monitor non-alcoholic fatty liver disease (NAFLD) and inflammation (NASH), chronic liver conditions that affect more than 1 billion people globally, and for which there are no practical diagnostic tools. Beyond the liver, ENDRA is exploring several other clinical applications of TAEUS including visualization of tissue temperature during energy-based surgical procedures.
Patent Nos. 11379343 (the ‘343 patent), 11392479 (the ‘479 patent) and 11405470 (the ‘470 patent) are titled, “Methods and Systems for Exchange of Equipment Performance Data.”
“We are pleased to be issued these three patents that, along with a previously issued U.S. patent, provide broad protection for our proprietary method to transfer equipment performance data to cloud-based services. In addition to protecting data management for our TAEUS system, these patents provide licensing opportunities with other equipment manufacturers,” ENDRA Chairman and CEO Francois Michelon said. "We continue to enhance our intellectual property portfolio to protect our technology in priority global markets. Our portfolio currently includes 53 patents issued globally, of which 31 patents are issued in the U.S.”
These three newly issued patents are part of a patent family that protects ENDRA’s proprietary method and system for acquiring, analyzing, and sharing data in the cloud. The ‘343 and ‘479 patents protect ENDRA's data sharing capabilities that are specific to the medical imaging industry. The ‘470 patent builds upon the company’s U.S. Patent No. 11314617 (the ‘617 patent). Both the ‘470 and ‘617 patents have claims that are narrower than the ‘343 and ‘479 patents and apply to industries outside of medical imaging. The ‘470 patent broadens ENDRA’s coverage from devices “not having internet connectivity” (as described in the ‘617 patent) to devices that are “communicatively insulated.”
ENDRA Life Sciences is the pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS), a technology being developed to visualize tissue like MRI, but a fraction of the cost and at the point of patient care. TAEUS is designed to work in concert with more than 500,000 ultrasound systems currently in use globally. TAEUS is initially focused on measuring liver fat as a means to assess and monitor non-alcoholic fatty liver disease (NAFLD) and inflammation (NASH), chronic liver conditions that affect more than 1 billion people globally, and for which there are no practical diagnostic tools. Beyond the liver, ENDRA is exploring several other clinical applications of TAEUS including visualization of tissue temperature during energy-based surgical procedures.
